URGENT UPDATE: Psychiatric pharmacists are calling for immediate policy changes to enhance treatment for substance use disorders (SUD) as new discussions unfold between experts in the field. Ashley Maister, PharmD, BCCP, from the US Department of Veterans Affairs, and Aaron Salwan, PharmD, MPH, BCCP, from Montefiore Nyack, highlight the critical role of interdisciplinary collaboration in improving patient outcomes and stress the need for expanded prescribing privileges.
In a revealing conversation with Pharmacy Times, Maister and Salwan detailed how psychiatric pharmacists work alongside physicians, case managers, social workers, and counselors to provide comprehensive care. They emphasized that without access to necessary medications, even the best treatment plans fail. Immediate action is required to overcome existing policy barriers that restrict pharmacists from prescribing vital medications like buprenorphine.
“Access to medications must be streamlined,” stated Salwan. “If we can identify a change in a patient’s behavior linked to medication adjustments, we have to discuss it with the entire care team—not just the physician. This collaborative approach is essential for effective treatment.”
Maister echoed this sentiment, arguing for the removal of the X-waiver that currently limits pharmacists’ ability to prescribe controlled substances. “Allowing psychiatric pharmacists to manage medications directly would greatly enhance continuity of care for our patients,” she asserted.
The experts pointed out that many states still impose stringent requirements on DEA licensure that hinder pharmacists from accessing necessary resources for patient care. “The current system creates unnecessary barriers that delay patient treatment,” Maister added.
The implications of these discussions are profound. With over 21 million Americans struggling with SUD, the need for effective treatment strategies is more urgent than ever. Expanding the roles of psychiatric pharmacists could not only improve patient outcomes but also streamline healthcare costs associated with SUD treatment.
Salwan highlighted the financial aspect, stating, “Many of the crucial services that pharmacists provide aren’t always reimbursed adequately, which limits their integration into health systems. This needs to change.”
Both experts agree that greater support for addiction services, including access to harm reduction tools like naloxone and sterile syringe programs, is necessary. These resources are vital in addressing the ongoing opioid crisis and ensuring comprehensive care for patients.
As discussions continue, the focus remains on how to implement these vital changes swiftly. The urgency to act is clear, as the consequences of inaction could further hinder recovery efforts for those affected by substance use disorders.
The call to action is resonating throughout the healthcare community, urging policymakers to recognize the essential role of psychiatric pharmacists. As this situation develops, the healthcare sector is poised for a significant shift in how SUD is treated, emphasizing collaboration and patient-centered care.
Stay tuned for further updates as the healthcare community rallies for change that could transform the landscape of SUD treatment.
